EUVIMED · CrossrefJournal
Translational Breast Cancer Research
ISSN 2218-6778 · AME Publishing Company
Latest articles
Role of circulating tumor cell clusters in breast cancer
Clinical practice guidelines for prognosis and follow-up of early-stage breast cancer patients: Chinese Society of Breast Surgery (CSBrS) practice guidelines (2026 edition) Chinese Society of Breast Surgery, Chinese Society of Surgery, Chinese Medical Association
Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?
Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses
The role of a national cancer registry in effective implementation and monitoring of the Global Breast Cancer Initiative (GBCI) framework in Ghana: a narrative review
Omission of breast surgery in exceptional responders after neoadjuvant chemotherapy—what are future possibilities?—a narrative review
Enhancing patient education in breast surgery: artificial intelligence-powered guidance for mastopexy, augmentation, reduction, and reconstruction
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review
De-escalation of axillary treatment in early breast cancer—a narrative review of current trials
Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy
Breast ultrasound knobology and the knobology of twinkling for marker detection
Pathological precision diagnosis and recent advances in HER2 low and ultralow in breast cancer: a narrative review
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024
Evolution of localization methods for non-palpable breast lesions: a literature review from a translational medicine perspective
Breast surgery after neoadjuvant systemic therapy
Narrative review on advancing breast cancer treatment: harnessing the power of PD-1/PD-L1 inhibitors for improved patient outcomes
Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives
Challenges in HER2-low breast cancer identification, detection, and treatment
Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
Androgen receptor in breast cancer and its clinical implication
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
Features and applications of Ehrlich tumor model in cancer studies: a literature review
Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer
Psychophysical effects of 4 months of outdoor winter mountain workouts in breast cancer survivors
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
CSCO breast cancer management guidelines 2022: Australian perspective
Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
The evolution and advances of biomarker use in clinical trials for breast cancer treatment—a narrative review
EUVIMED